Cyclacel Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 ASH Annual Meeting

Cyclacel Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 ASH Annual Meeting

[at noodls] – Median Overall Survival is 238 days, or Approximately 8 Months, and 1-Year Survival is 35% With an Overall Response Rate of 41% in Elderly Patients With Newly Diagnosed AML BERKELEY HEIGHTS, N.J., Dec. … more

View todays social media effects on CYCC

View the latest stocks trending across Twitter. Click to view dashboard

See who Cyclacel is hiring next, click here to view

Share this post